INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours

Most Recent Events

  • 09 Feb 2018 Incyte Corporation plans the phase I CITADEL-112 trial for B-cell lymphoma in USA in June 2018 (NCT03424122)
  • 09 Dec 2017 Updated efficacy and adverse events data from the phase I/II CITADEL-101 trial in B-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 25 Oct 2017 Incyte Corporation plans the phase I CITADEL-111 trial for B-cell lymphoma (Second-line therapy or greater) in June 2018 (NCT03314922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top